TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07838220: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,201,744

Rescue Site Savings

+$4,763,536

Unlock Full NCT07838220 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07838220 Rescue Dossier →